Mironid

Mironid is a clinical-stage biopharmaceutical company developing novel small-molecule therapeutics that target cAMP-degrading phosphodiesterase (PDE4) enzymes for rare kidney and lung diseases, with a primary focus on Autosomal Dominant Polycystic Kidney Disease (ADPKD). The company's pipeline includes PDE4 activators and inhibitors designed to modulate central signalling mechanisms that drive ADPKD and inflammatory/fibrotic lung conditions, addressing diseases with significant unmet medical need. Headquartered in Glasgow, UK, Mironid is backed by Epidarex Capital and is building a differentiated pipeline of drug candidates across multiple rare disease indications.